620 related articles for article (PubMed ID: 35499301)
21. Effectiveness of Booster Vaccinations on the Control of COVID-19 during the Spread of Omicron Variant in Malaysia.
Wong MTJ; Dhaliwal SS; Balakrishnan V; Nordin F; Norazmi MN; Tye GJ
Int J Environ Res Public Health; 2023 Jan; 20(2):. PubMed ID: 36674401
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity of a fractional or full third dose of AZD1222 vaccine or BNT162b2 messenger RNA vaccine after two doses of CoronaVac vaccines against the Delta and Omicron variants.
Niyomnaitham S; Jongkaewwattana A; Meesing A; Pinpathomrat N; Nanthapisal S; Hirankarn N; Siwamogsatham S; Kirdlarp S; Chaiwarith R; Lawpoolsri S; Phanthanawiboon S; Thitithanyanont A; Hansasuta P; Chaiyaroj S; Pitisuttithum P
Int J Infect Dis; 2023 Apr; 129():19-31. PubMed ID: 36682680
[TBL] [Abstract][Full Text] [Related]
23. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen.
Baek YJ; Kim WJ; Ko JH; Lee YJ; Ahn JY; Kim JH; Jang HC; Jeong HW; Kim YC; Park YS; Kim SH; Peck KR; Shin EC; Choi JY
Vaccine; 2023 Mar; 41(10):1694-1702. PubMed ID: 36754764
[TBL] [Abstract][Full Text] [Related]
24. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
[TBL] [Abstract][Full Text] [Related]
25. Neutralizing Activity Against SARS-CoV-2 Delta and Omicron Variants Following a Third BNT162b2 Booster Dose According to Three Homologous or Heterologous COVID-19 Vaccination Schedules.
Choi JY; Lee YJ; Ko JH; Kim SH; Kim HJ; Lee HW; Jeong H; Kim TY; Jang YG; Hong HJ; Kim MS; Lee SE; Kim YG; Chung EJ; Lim H; Jang S; Kim K; Kim SS; Ahn JY; Choi JY; Kim YC; Park YS; Peck KR; Kim B
Front Cell Infect Microbiol; 2022; 12():948014. PubMed ID: 35899050
[TBL] [Abstract][Full Text] [Related]
26. Vaccine effectiveness of BNT162b2 and CoronaVac against SARS-CoV-2 omicron infection and related hospital admission among people with substance use disorder in Hong Kong: a matched case-control study.
Huang C; Wei Y; Yan VKC; Ye X; Kang W; Yiu HHE; Shami JJP; Cowling BJ; Tse ML; Castle DJ; Chui CSL; Lai FTT; Li X; Wan EYF; Wong CKH; Hayes JF; Chang WC; Chung AKK; Lau CS; Wong ICK; Chan EW
Lancet Psychiatry; 2023 Jun; 10(6):403-413. PubMed ID: 37141907
[TBL] [Abstract][Full Text] [Related]
27. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
Menni C; May A; Polidori L; Louca P; Wolf J; Capdevila J; Hu C; Ourselin S; Steves CJ; Valdes AM; Spector TD
Lancet Infect Dis; 2022 Jul; 22(7):1002-1010. PubMed ID: 35405090
[TBL] [Abstract][Full Text] [Related]
28. Immunological responses and adverse reactions of the heterologous second booster dose of BNT162b2 after two-dose CoronaVac for COVID-19 vaccination in healthcare workers of Faculty of Medicine, Naresuan University.
Makanut S; Wangteeraprasert A; Jitpewngam W; Ngoenkam J; Pongcharoen S
Vaccine; 2023 Jun; 41(29):4335-4340. PubMed ID: 37301707
[TBL] [Abstract][Full Text] [Related]
29. Boosting with Multiple Doses of mRNA Vaccine after Priming with Two Doses of Protein Subunit Vaccine MVC-COV1901 Elicited Robust Humoral and Cellular Immune Responses against Emerging SARS-CoV-2 Variants.
Chiu CH; Chang YH; Tao CW; Chang FY; Chiu KC; Chang TW; Yen LC
Microbiol Spectr; 2022 Oct; 10(5):e0060922. PubMed ID: 36005765
[TBL] [Abstract][Full Text] [Related]
30. A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines.
Nanthapisal S; Puthanakit T; Jaru-Ampornpan P; Nantanee R; Sodsai P; Himananto O; Sophonphan J; Suchartlikitwong P; Hiransuthikul N; Angkasekwinai P; Tangsathapornpong A; Hirankarn N;
Vaccine; 2022 Apr; 40(18):2551-2560. PubMed ID: 35341647
[TBL] [Abstract][Full Text] [Related]
31. Safety and immunogenicity of intradermal administration of fractional dose CoronaVac
Chatsiricharoenkul S; Niyomnaitham S; Posen HJ; Toh ZQ; Licciardi PV; Wongprompitak P; Duangchinda T; Pakchotanon P; Chantima W; Chokephaibulkit K
Front Immunol; 2022; 13():1010835. PubMed ID: 36268028
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data.
Wanlapakorn N; Suntronwong N; Phowatthanasathian H; Yorsaeng R; Thongmee T; Vichaiwattana P; Auphimai C; Wongsrisang L; Klinfueng S; Sudhinaraset N; Poovorawan Y
Vaccine; 2022 May; 40(23):3203-3209. PubMed ID: 35465981
[TBL] [Abstract][Full Text] [Related]
33. Impact of COVID-19 Vaccination on Healthcare Worker Infection Rate and Outcome during SARS-CoV-2 Omicron Variant Outbreak in Hong Kong.
Zee ST; Kwok LF; Kee KM; Fung LH; Luk WP; Chan TL; Leung CP; Yu PW; Hung J; SzeTo KY; Chan WL; Tang SF; Lin WC; Ma SK; Lee KH; Lau CC; Yung WH
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016210
[TBL] [Abstract][Full Text] [Related]
34. Humoral immune response in people living with HIV after administration of SARS-CoV-2 vaccine CoronaVac or BNT162b2 or CoronaVac/BNT162b2 booster sequence: A cross-sectional study.
Wolff M; Charpentier P; Canals A; Vial C; Hormazábal J; Cortés J; Silva M
Vaccine; 2024 Jan; 42(3):671-676. PubMed ID: 38123398
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent impairment in antibody responses elicited by a homologous CoronaVac booster dose.
Filardi BA; Monteiro VS; Schwartzmann PV; do Prado Martins V; Zucca LER; Baiocchi GC; Malik AA; Silva J; Hahn AM; Chen NFG; Pham K; Pérez-Then E; Miric M; Brache V; Cochon L; Larocca RA; Mendez RDR; Bardini Silveira D; Pinto AR; Croda J; Yildirim I; Omer SB; Ko AI; Vermund SH; Grubaugh ND; Iwasaki A; Lucas C; ; Vogels CBF; Breban M; Koch TR; Chaguza C; Tikhonova I; Castaldi C; Mane S; De Kumar B; Ferguson D; Kerantzas N; Peaper D; Landry ML; Schulz W
Sci Transl Med; 2023 Feb; 15(683):eade6023. PubMed ID: 36791210
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study.
Tawinprai K; Jungsomsri P; Pinijnai O; Tavonvunchai F; Lievjaroen A; Suwannaroj P; Siripongboonsitti T; Porntharukchareon T; Sornsamdang G; Ungtrakul T
Hum Vaccin Immunother; 2023 Dec; 19(1):2206360. PubMed ID: 37140889
[TBL] [Abstract][Full Text] [Related]
37. BNT162b2 booster after heterologous prime-boost vaccination induces potent neutralizing antibodies and T cell reactivity against SARS-CoV-2 Omicron BA.1 in young adults.
Seidel A; Zanoni M; Groß R; Krnavek D; Erdemci-Evin S; von Maltitz P; Albers DPJ; Conzelmann C; Liu S; Weil T; Mayer B; Hoffmann M; Pöhlmann S; Beil A; Kroschel J; Kirchhoff F; Münch J; Müller JA
Front Immunol; 2022; 13():882918. PubMed ID: 35958601
[TBL] [Abstract][Full Text] [Related]
38. Expert review on global real-world vaccine effectiveness against SARS-CoV-2.
Chuenkitmongkol S; Solante R; Burhan E; Chariyalertsak S; Chiu NC; Do-Van D; Husin M; Hwang KP; Kiertiburanakul S; Kulkarni PS; Lee PI; Lobo RC; Nghia CH; Ong-Lim A; Sivasampu S; Suah JL; Tok PSK; Thwaites G;
Expert Rev Vaccines; 2022 Sep; 21(9):1255-1268. PubMed ID: 35748494
[TBL] [Abstract][Full Text] [Related]
39. Interdependencies of cellular and humoral immune responses in heterologous and homologous SARS-CoV-2 vaccination.
Hollstein MM; Münsterkötter L; Schön MP; Bergmann A; Husar TM; Abratis A; Eidizadeh A; Schaffrinski M; Zachmann K; Schmitz A; Holsapple JS; Stanisz-Bogeski H; Schanz J; Fischer A; Groß U; Leha A; Zautner AE; Schnelle M; Erpenbeck L
Allergy; 2022 Aug; 77(8):2381-2392. PubMed ID: 35124800
[TBL] [Abstract][Full Text] [Related]
40. Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil.
Cerqueira-Silva T; de Araujo Oliveira V; Paixão ES; Júnior JB; Penna GO; Werneck GL; Pearce N; Barreto ML; Boaventura VS; Barral-Netto M
Nat Commun; 2022 Jul; 13(1):4154. PubMed ID: 35851597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]